Respiri's strategic advantage with AMA changes

Respiri (ASX:RSH), an eHealth SaaS company, has announced expected significant revenue growth from upcoming American Medical Association (AMA) changes in Remote Patient Monitoring (RPM) reimbursement. These changes, effective January 2026, will simplify criteria and enhance access for patients, benefiting Respiri's services.

Respiri's RPM outlook and strategy

Respiri is set to benefit from the AMA's proposed changes to RPM reimbursement criteria, which will likely increase patient eligibility for monthly reimbursements from 50%-70% to 90%. This could potentially lead to over US$108K additional annual revenue per 1,000 patients. The company also anticipates a doubling in monitoring services by its clinical staff and a rise in per patient fees. These changes align with Respiri's strategy of providing comprehensive Connected Care Management programs aimed at reducing hospital re-admissions and emergency visits. The AMA's endorsement of RPM underscores its value in healthcare, and Respiri is poised to capitalize on this with its FDA-cleared wheezo® device. However, the company advises caution as forward-looking statements are subject to risks and uncertainties.

Executive insights on RPM changes

CEO Marjan Mikel emphasized the importance of RPM in reducing healthcare costs and improving patient outcomes. The proposed changes confirm the strategic direction of Respiri in delivering effective healthcare solutions.